Magnetic resonance perfusion imaging in neuro-oncology

Cancer Imaging

Volumn 8, Issue 1, 2008, Pages 186-199

  Jackson, Alan ^a   O'Connor, James ^a   Thompson, Gerard ^a   Mills, Samantha ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cerebral tumour; Dynamic imaging; Functional imaging; Glioma; Magnetic resonance imaging (MRI); Meningioma; Perfusion; Permeability

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; IRINOTECAN; TEMOZOLOMIDE; THALIDOMIDE;

CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; GLIOMA; HUMAN; NEUROIMAGING; NEUROLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; PERFUSION WEIGHTED IMAGING; QUANTITATIVE ANALYSIS; REVIEW; TUMOR VASCULARIZATION;

HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; NEOPLASMS, NERVE TISSUE; NEOVASCULARIZATION, PATHOLOGIC;

EID: 55149123392     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2008.0019     Document Type: Review

References (126)

1. Jackson A, Buckley DL, Parker GJM, editors. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Berlin: Springer-Verlag; 2005, p. 1-311.
2. Biomarkers Definitions Working Group.Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
3. Lund EL, Spang-Thomsen M, Skovgaard-Poulsen H, Kristjansen PE. Tumor angiogenesis - a new therapeutic target in gliomas. Acta Neurol Scand 1998; 97: 52-62.
4. Zhu XP, Li KL, Kamaly-Asl ID, Waterton J, Jackson A. Quantification of endothelial permeability, leakage space and blood volume in brain tumors using combined T1 and T2* contrast-enhanced dynamic MR imaging. J Magn Reson Imaging 2000; 11: 575-85.
5. Jayson GC, Zweit J, Jackson A et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002; 94: 1484-93.
6. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96: 189-95.
7. Kassner A, Annesley D, Zhu XP et al. Abnormalities of the contrast re-circulation phase in cerebral tumors demonstrated using dynamic susceptibility contrast-enhanced imaging: a possible marker of vascular tortuosity. J Magn Reson Imaging 2000; 11: 103-13.
8. Uematsu H, Maeda M, Sadato N et al. Vascular permeability: quantitative measurement with double-echo dynamic MR imaging - theory and clinical application. Radiology 2000; 214: 912-7.
9. Knopp MV, Weiss E, Sinn HP, Gaa J, Laub G, Wielopolski P. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999; 10: 260-6.
10. Edelman RR, Siewert B, Adamis M et al. Signal targeting with alternating radiofrequency (STAR) sequences: application to MR angiography. Magn Reson Med 1994; 31: 233-8.
11. Kwong KK, Chesler DA, Weisskoff RM et al. MR perfusion studies with T1-weighted echo planar imaging. Magn Reson Med 1995; 34: 878-87.
12. Kim SG. Quantification of relative cerebral blood flow change by flow-sensitive alternating inversion recovery (FAIR) technique: application to functional mapping. Magn Reson Med 1995; 34: 293-301.
13. Golay X, Hendrikse J, Lim TC. Perfusion imaging using arterial spin labeling. Top Magn Reson Imaging 2004; 15: 10-27.
14. Rosen BR, Belliveau JW, Buchbinder BR et al. Contrast agents and cerebral hemodynamics. Magn Reson Med 1991; 19: 285-92.
15. Calamante F, Thomas DL, Pell GS, Wiersma J, Turner R. Measuring cerebral blood flow using magnetic resonance imaging techniques. J Cereb Blood Flow Metab 1999; 19: 701-35.
16. Jackson A. Analysis of dynamic contrast enhanced MRI. Br J Radiol 2004; 77: S154-66.
17. Barbier EL, Lamalle L, Decorps M. Methodology of brain perfusion imaging. J Magn Reson Imaging 2001; 13: 496-520.
18. Sorensen A, Reimer P. Cerebral MR perfusion imaging: principles and current applications. Vol. 152. Stuttgart: Thieme; 2000.
19. Boxerman JL, Hamberg L, Rosen B, Weisskoff RM. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995; 34: 555-66.
20. 2O positron emission tomography in humans. J Cereb Blood Flow Metab 1998; 18: 935-40.
21. Rosen BR, Belliveau JW, Aronen HJ et al. Susceptibility contrast imaging of cerebral blood volume: human experience. Magn Reson Med 1991; 22: 293-9 (discussion 300-3).
22. Calamante F, Gadian DG, Connelly A. Delay and dispersion effects in dynamic susceptibility contrast MRI: simulations using singular value decomposition. Magn Reson Med 2000; 44: 466-73.
23. Weisskoff RM, Zuo CS, Boxerman JL, Rosen BR. Microscopic susceptibility variation and transverse relaxation: theory and experiment. Magn Reson Med 1994; 31: 601-10.
24. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95.
25. Donahue KM, Krouwer HG, Rand SD et al. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med 2000; 43: 845-53.
26. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
27. Buckley DL, Parker GJM. Measuring contrast agent concentration in T1-weighted dynamic contrast-enhanced MRI. In: Jackson A, Buckley DL, Parker GJM, editors. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Berlin: Springer-Verlag; 2005, p. 69-79.
28. Parker GJ, Roberts C, Macdonald A et al. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med 2006; 56: 993-1000.
29. Li KL, Zhu XP, Jackson A. Parametric mapping of scaled fitting error in dynamic susceptibility contrast enhanced MR perfusion imaging. Br J Radiol 2000; 73: 470-81.
30. Li KL, Zhu XP, Waterton J, Jackson A. Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors. J Magn Reson Imaging 2000; 12: 347-57.
31. Parker GJM, Buckley DL. Tracer kinetic modelling for T1-weighted DCE-MRI. In: Jackson A, Buckley DL, Parker GJM, editors. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Berlin: Springer-Verlag; 2005, p. 81-92.
32. Stack JP, Redmond O, Codd M, Dervan P, Ennis J. Breast disease: tissue characterization with Gd-DTPA enhancement profiles. Radiology 1990; 174: 491-4.
33. Flickinger FW, Allison J, Sherry R et al. Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI. Magn Reson Imaging 1993; 11: 617-20.
34. Roberts C, Issa B, Stone A, Jackson A, Waterton J, Parker G. Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. J Magn Reson Imaging 2006; 23: 554-63.
35. Maeda M, Itoh S, Kimura H et al. Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. Radiology 1993; 189: 233-8.
36. Provenzale JM, York G, Moya MG et al. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms. AJR Am J Roentgenol 2006; 187: 1036-42.
37. Cha S, Lupo JM, Chen MH et al. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2007; 28: 1078-84.
38. Lupo JM, Cha S, Chang SM, Nelson SJ. Dynamic susceptibilityweighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. AJNR Am J Neuroradiol 2005; 26: 1446-54.
39. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997; 7: 91-101.
40. Tofts PS, Brix G, Buckley DL et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223-32.
41. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. Magn Reson Med 1991; 17: 357-67.
42. Padhani AR, Husband JE. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 2001; 56: 607-20.
43. Leach MO, Brindle KM, Evelhoch JL et al. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol 2003; 76: S87-91.
44. Leach MO, Brindle KM, Evelhoch JL et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005; 92: 1599-610.
45. trans measurements obtained with conventional and first pass pharmacokinetic models in human gliomas. J Magn Reson Imaging 2004; 19: 527-36.
46. St Lawrence KS, Lee TY. An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: I. Theoretical derivation. J Cereb Blood Flow Metab 1998; 18: 1365-77.
47. Calamante F, Gadian DG, Connelly A. Quantification of perfusion using bolus tracking magnetic resonance imaging in stroke: assumptions, limitations, and potential implications for clinical use. Stroke 2002; 33: 1146-51.
48. Ostergaard L, Hochberg FH, Rabinov JD et al. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg 1999; 90: 300-5.
49. Thacker NA, Scott ML, Jackson A. Can dynamic susceptibility contrast magnetic resonance imaging perfusion data be analyzed using a model based on directional flow? J Magn Reson Imaging 2003; 17: 241-55.
50. St Lawrence KS, Lee TY. An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: II. Experimental validation. J Cereb Blood Flow Metab 1998; 18: 1378-85.
51. Jayson GC, Parker GJ, Mullamitha S et al. Blockade of plateletderived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 2005; 23: 973-81.
52. Buckley DL. Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn Reson Med 2002; 47: 601-6.
53. Haroon HA, Patankar TF, Zhu XP et al. Comparison of cerebral blood volume maps generated from T2* and T1 weighted MRI data in intra-axial cerebral tumours. Br J Radiol 2007; 80: 161-8.
54. Erdogan C, Hakyemez B, Yildirim N, Parlak M. Brain abscess and cystic brain tumor: discrimination with dynamic susceptibility contrast perfusion-weighted MRI. J Comput Assist Tomogr 2005; 29: 663-7.
55. Holmes TM, Petrella JR, Provenzale JM. Distinction between cerebral abscesses and high-grade neoplasms by dynamic susceptibility contrast perfusion MRI. AJR Am J Roentgenol 2004; 183: 1247-52.
56. Foo SS, Abbott D, Lawrentschuk N, Scott A. Functional imaging of intratumoral hypoxia. Mol Imaging Biol 2004; 6: 291-305.
57. Bink A, Gaa J, Franz K et al. Importance of diffusion-weighted imaging in the diagnosis of cystic brain tumors and intracerebral abscesses. Zentralbl Neurochir 2005; 66: 119-25.
58. Mascalchi M, Filippi M, Floris R, Fonda C, Gasparrotti R, Villari N. Diffusion-weighted MR of the brain: methodology and clinical application. Radiol Med (Torino) 2005; 109: 155-97.
59. Fujii K, Fujita N, Hirabuki N, Hashimoto T, Miura T, Kozuka T. Neuromas and meningiomas: evaluation of early enhancement with dynamic MR imaging. AJNR Am J Neuroradiol 1992; 13: 1215-20.
60. Nagele T, Petersen D, Klose U et al. Dynamic contrast enhancement of intracranial tumors with snapshot-FLASH MR imaging. AJNR Am J Neuroradiol 1993; 14: 89-98.
61. Sugahara T, Korogi Y, Shigematsu Y et al. Value of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of intracranial tumors. Top Magn Reson Imaging 1999; 10: 114-24.
62. Maeda M, Itoh S, Kimura H et al. Vascularity of meningiomas and neuromas: assessment with dynamic susceptibility-contrast MR imaging. AJR Am J Roentgenol 1994; 163: 181-6.
63. Miyati T, Banno T, Mase M et al. Dual dynamic contrastenhanced MR imaging. J Magn Reson Imaging 1997; 7: 230-5.
64. Long DM. Vascular ultrastructure in human meningiomas and schwannomas. J Neurosurg 1973; 38: 409-19.
65. Hakyemez B, Yildirim N, Erdogan C, Kocaeli H, Korfali E, Parlak M. Meningiomas with conventional MRI findings resembling intraaxial tumors: can perfusion-weighted MRI be helpful in differentiation? Neuroradiology 2006; 48: 695-702.
66. Yang S, Law M, Zagzag D et al. Dynamic contrast-enhanced perfusion MR imaging measurements of endothelial permeability: differentiation between atypical and typical meningiomas. AJNR Am J Neuroradiol 2003; 24: 1554-9.
67. Cha S, Knopp EA, Johnson G, Wetzel SG, Litt AW, Zagzag D. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002; 223: 11-29.
68. Calli C, Kitis O, Yunten N, Yurtseven T, Islekel S, Akalin T. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 2006; 58: 394-403.
69. Weber MA, Zoubaa S, Schlieter M et al. Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors. Neurology 2006; 66: 1899-906.
70. Law M, Kazmi K, Wetzel S et al. Dynamic susceptibility contrast-enhanced perfusion and conventional MR imaging findings for adult patients with cerebral primitive neuroectodermal tumors. AJNR Am J Neuroradiol 2004; 25: 997-1005.
71. Rollin N, Guyotat J, Streichenberger N, Honnorat J, Tran Minh V-A, Cotton F. Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors. Neuroradiology 2006; 48: 150-9.
72. Cha S, Law M, Johnson G et al. Peritumoral region: differentiation between primary high-grade neoplasm and solitary metastasis using dynamic contrast-enhanced T2*-weighted echo-planar perfusion MR imaging. In: Proceedings of the 38th Annual Meeting of the American Society of Neuroradiology, 2000, Atlanta, GA.
73. Chiang IC, Kuo YT, Lu CY et al. Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology 2004; 46: 619-27.
74. Strugar J, Rothbart D, Harrington W, Criscuolo GR. Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis. J Neurosurg 1994; 81: 560-6.
75. Strugar JG, Criscuolo GR, Rothbart D, Harrington W. Vascular endothelial growth/permeability factor expression in human glioma specimens: correlation with vasogenic brain edema and tumor-associated cysts. J Neurosurg 1995; 83: 682-9.
76. Knopp EA, Cha S, Johnson G et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999; 211: 791-8.
77. Di Costanzo A, Scarabino T, Trojsi F et al. Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancy. Neuroradiology 2006; 48: 622-31.
78. Patankar TF, Haroon HA, Mills SJ et al. Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas? AJNR Am J Neuroradiol 2005; 26: 2455-65.
79. Law M, Yang S, Babb JS et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004; 25: 746-55.
80. Warmuth C, Gunther M, Zimmer C. Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 2003; 228: 523-32.
81. Brown GG, Clark C, Liu TT. Measurement of cerebral perfusion with arterial spin labeling: Part 2. Applications. J Int Neuropsychol Soc 2007; 13: 526-38.
82. Kimura H, Takeuchi H, Koshimoto Y et al. Perfusion imaging of meningioma by using continuous arterial spin-labeling: comparison with dynamic susceptibility-weighted contrast-enhanced MR images and histopathologic features. AJNR Am J Neuroradiol 2006; 27: 85-93.
83. Aronen HJ, Glass J, Pardo FS et al. Echo-planar MR cerebral blood volume mapping of gliomas. Clinical utility. Acta Radiol 1995; 36: 520-8.
84. Sugahara T, Korogi Y, Kochi M et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998; 171: 1479-86.
85. Roberts HC, Roberts TP, Brasch RC, Dillon WP. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000; 21: 891-9.
86. Roberts HC, Roberts TP, Bollen AW, Ley S, Brasch RC, Dillon WP. Correlation of microvascular permeability derived from dynamic contrast-enhanced MR imaging with histologic grade and tumor labeling index: a study in human brain tumors. Acad Radiol 2001; 8: 384-91.
87. Pathak AP, Schmainda KM, Ward BD, Linderman JR, Rebro KJ, Greene AS. MR-derived cerebral blood volume maps: issues regarding histological validation and assessment of tumor angiogenesis. Magn Reson Med 2001; 46: 735-47.
88. Aronen HJ, Pardo FS, Kennedy DN et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000; 6: 2189-200.
89. Sadeghi N, Salmon I, Tang BN et al. Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: preliminary results. J Magn Reson Imaging 2006; 24: 989-94.
90. Grosu AL, Piert M, Weber WA et al. Positron emission tomography for radiation treatment planning. Strahlenther Onkol 2005; 181: 483-99.
91. Grosu AL, Weber WA, Franz M et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63: 511-9.
92. Lam WW, Chan KW, Wong WL, Poon WS, Metriweli C. Pre-operative grading of intracranial glioma. Acta Radiol 2001; 42: 548-54.
93. Wong ET, Jackson EF, Hess KR et al. Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology 1998; 50: 777-81.
94. Hawighorst H, Knopp MV, Debus J et al. Pharmacokinetic MRI for assessment of malignant glioma response to stereotactic radiotherapy: initial results. J Magn Reson Imaging 1998; 8: 783-8.
95. Lev MH, Ozsunar Y, Henson JW et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004; 25: 214-21.
96. Law M, Oh S, Babb JS et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging - prediction of patient clinical response. Radiology 2006; 238: 658-67.
97. Chaskis C, Stadnik T, Michotte A, Van Rompaey K, D'Haens J. Prognostic value of perfusion-weighted imaging in brain glioma: a prospective study. Acta Neurochir (Wien) 2006; 148: 277-85; discussion 285.
98. Cao Y, Tsien CI, Nagesh V et al. Survival prediction in highgrade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys 2006; 64: 876-85.
99. Mills SJ, Patankar TA, Haroon HA, Balériauxc D, Swindellb R, Jackson A. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 2006; 27: 853-8.
100. Roux FX, Nataf F. Cerebral oligodendrogliomas in adults and children. Current data and perspectives. Neurochirurgie 2005; 51: 410-4.
101. Cairncross JG, Ueki K, Zlatescu KC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473-9.
102. Ino Y, Betensky RA, Zlatescu MC et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001; 7: 839-45.
103. Xu M, See SJ, Ng WH et al. Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 2005; 56: 919-26; discussion 919-26.
104. White ML, Zhang Y, Kirby P, Ryken TC. Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol 2005; 26: 784-90.
105. Jenkinson MD, Smith TS, Joyce KA et al. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 2006; 48: 703-13.
106. Law M, Brodsky JE, Babb J et al. High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: preliminary results of molecular studies in gliomas with elevated perfusion. J Magn Reson Imaging 2007; 25: 1113-9.
107. Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker FG. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 2005; 11: 8600-5.
108. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991; 64: 769-74.
109. Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002; 64: 259-73.
110. Wenz F, Rempp K, Hess T et al. Effect of radiation on blood volume in low-grade astrocytomas and normal brain tissue: quantification with dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 1996; 166: 187-93.
111. Fuss M, Wenz F, Scholdei R et al. Radiation-induced regional cerebral blood volume (rCBV) changes in normal brain and low-grade astrocytomas: quantification and time and dose-dependent occurrence. Int J Radiat Oncol Biol Phys 2000; 48: 53-8.
112. Alavi JB, Alavi A, Chawluk A et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988; 62: 1074-8.
113. Frahm J, Haase A, Matthaei D. Rapid three-dimensional MR imaging using the FLASH technique. J Comput Assist Tomogr 1986; 10: 363-8.
114. Reinhold HS, Endrich B. Tumour microcirculation as a target for hyperthermia. Int J Hyperthermia 1986; 2: 111-37.
115. Song CW, Lokshina A, Rhee JG, Patten M, Levitt SH. Implication of blood flow in hyperthermic treatment of tumors. IEEE Trans Biomed Eng 1984; 31: 9-16.
116. Rosen BR, Aronen HJ, Kwong KK, Belliveau JW, Hamberg LM, Fordham JA. Advances in clinical neuroimaging: functional MR imaging techniques. Radiographics 1993; 13: 889-96.
117. Gobbel GT, Seilhan TM, Fike JR. Cerebrovascular response after interstitial irradiation. Radiat Res 1992; 130: 236-40.
118. Herholz K, Coope D, Jackson A. Metabolic and molecular imaging in neuro-oncology. Lancet Neurol 2007; 6: 711-24.
119. Leimgruber A, Ostermann S, Yeon EJ et al. Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. Int J Radiat Oncol Biol Phys 2006; 64: 869-75.
120. 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 2006; 33: 516-24.
121. Cha S, Knopp EA, Johnson G et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 2000; 21: 881-90.
122. Jackson A, Kassner A, Annesley-Williams D, Reid H, Zhu XP, Li KL. Abnormalities in the recirculation phase of contrast agent bolus passage in cerebral gliomas: comparison with relative blood volume and tumor grade. AJNR Am J Neuroradiol 2002; 23: 7-14.
123. Jackson A, Kassner A, Zhu XP, Li KL. Reproducibility of T2* blood volume and vascular tortuosity maps in cerebral gliomas. J Magn Reson Imaging 2001; 14: 510-6.
124. Jackson A, O'Connor JPB, Parker GJM, Jayson GC. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 2007; 13: 3449-59.
125. Rijpkema M, Schuuring J, Bernsen PL et al. BOLD MRI response to hypercapnic hyperoxia in patients with meningiomas: correlation with gadolinium-DTPA uptake rate. Magn Reson Imaging 2004; 22: 761-7.
126. Rauscher A, Sedlacik J, Fitzek C et al. High resolution susceptibility weighted MR-imaging of brain tumors during the application of a gaseous agent. Rofo 2005; 177: 1065-9.